DOCSLIB.ORG

Hazardous Drug List PHARMACY Handling Categories Category A1 (Low Risk): Primarily Oral Solids That Are Not Anti-Neoplastics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hazardous Drug List PHARMACY Handling Categories Category A1 (Low Risk): Primarily Oral Solids That Are Not Anti-Neoplastics Sarasota Memorial Hospital Hazardous Drug List PHARMACY Handling Categories Category A1 (Low Risk): Primarily oral solids that are not anti-neoplastics. May be tubed and placed in Pyxis • Personal protective equipment not required for dispensing prepackaged intact drug product not requiring manipulation. • Oral solids requiring repackaging: Single pair of chemotherapy gloves. • Oral solids requiring cutting, crushing, or other manipulation will be considered a category B2 (medium risk) hazardous drug, requiring double pair of chemotherapy gloves and chemotherapy gown. Mask required if powder inhalation is a risk. Category A2 (Low-Medium Risk): Primarily anti-neoplastic oral solids - Hand delivered only/Not in Pyxis • Require the same precautions and personal protective equipment as Handling Category A1 above PLUS: • These agents will not be placed in Pyxis and cannot be delivered through the pneumatic tube system and must be hand carried. Category B1 (Medium Risk): Primarily oral liquids, topicals, and injections that are not anti-neoplastics- May be tubed and placed in Pyxis • Personal protective equipment not required for dispensing prepackaged or previously prepared intact product not requiring manipulation. • Drug product requiring repackaging, compounding, or manipulation: Double pair of chemotherapy gloves and chemotherapy gown. Mask required if sterile product or if powder inhalation is a risk. Category B2 (Medium Risk): Antineoplastic oral liquids, topicals, or injections not requiring manipulation and crushed/manipulated HD oral solids. Not tubed/Not in Pyxis • Personal protective equipment not required for dispensing prepackaged or previously prepared intact product not requiring manipulation. • Drug product requiring repackaging, compounding, or manipulation: Double pair of chemotherapy gloves and chemotherapy gown. Mask required if sterile product or if powder inhalation is a risk. Category C (High Risk): Primarily antineoplastic injections. Hand delivered only/Not in Pyxis • Double pair of chemotherapy gloves and chemotherapy gown are required. Outermost gloves must be sterile. • Must be compounded in a ventilated engineering control, utilizing hair/beard cover, mask, and double shoe covers. NURSING Handling Categories Handling Category A (Low Risk): ): Primarily oral solids • Single pair of chemotherapy gloves required. • Crushed tablets or opened capsules: Treat as Category B. Double pair of chemotherapy gloves and face protection (mask) required to avoid inhalation of powder. Crushing tablets or opening of capsules must be performed in pharmacy. Handling Category B (Medium Risk): Primarily oral liquids, injections, topicals, and crushed or manipulated oral solids • Double pair of chemotherapy gloves required. • Chemotherapy gown recommended if there is a splash potential or risk of spitting or vomiting of the dose after administration. Handling Category C (High Risk): Primarily antineoplastic injections • Double pair of chemotherapy gloves, and chemotherapy gown required (see also Nursing Procedure onc 01). Definitions (See Exposure Risk Information Section) • IARC: International Agency for Research on Cancer Antineoplastic: Inhibits or prevents the spreaD of tumors or malignant cells o Group 1: Carcinogenic to humans Black Box warning: The most significant warning for prescription drugs by the FDA when use of a drug has been o Group 2A: Probably carcinogenic to humans associated with serious harm o Group 2B: Possibly carcinogenic to humans Carcinogen: A substance capable of causing cancer in living tissue • NTP: National Toxicology Program classification Carcinoma: Cancer arising in the epithelial tissue of the skin or the lining of the internal organs o NTP** Known to be a human carcinogen Genotoxic: Able to cause damage to the genetic information within a cell o NTP*** Reasonably anticipated to be a human carcinogen Lymphoma: Cancer of the lymph noDes • FDA Pregnancy Categories: FDA Drug categorization baseD on risk of use During pregnancy Malignant: SpreaD of cancer to nearby tissues anD other areas of the boDy o Category A: Adequate human studies have not shown a risk to the fetus Neoplasm: New abnormal tissue growth, particularly relateD to cancer o Category B: Animal studies have not shown a risk to the fetus Teratogenic: Use has the potential for causing malformations to an embryo st nd rd o Category C: Animal studies have shown a risk to the fetus, human studies have not Trimesters: 1 : Initial 12 weeks of gestation; 2 : Time from 13 weeks to 27 weeks of gestation; 3 : Time from o Category D: Evidence of risk to the fetus; benefits of medication may outweigh the risks 28 weeks of gestation until Delivery o Category X: Evidence of risk to the fetus; risks of meDication clearly outweigh benefits Generic Drug Name NIOSH Group Formulation Pharmacy Nursing Exposure Risk Information (Brand Name) Handling Handling NIOSH Supplemental Information Pregnancy Category Category Category Abacavir Non- Malignant tumors observeD in male anD female mice Oral SoliD A1 A C (Ziagen) Antineoplastic anD rats; genotoxic in in vivo micronucleus test Acitretin Reproductive Oral SoliD A1 A Black Box warning on severe reproductive effects X (Soriatane) Risk Altretamine Antineoplastic Oral SoliD A2 A D (Hexalen) Anastrazole Antineoplastic Oral SoliD A2 A X (ArmiDex) Arsenic Trioxide Antineoplastic Injection C C IARC Group 1 carcinogen; NTP** D (Trisenox) Azacitidine Antineoplastic Injection C C IARC Group 2A carcinogen; NTP*** D (ViDaza) Azathioprine Non- Oral SoliD A2 A IARC Group 1 carcinogen; NTP* D (Imuran) Antineoplastic Injection C C May cause teratogenicity anD/or embryo-fetal lethality Belinostat Antineoplastic Injection C C because it is a genotoxic drug and targets actively D (BeleoDaq) dividing cells Bendamustine Antineoplastic Injection C C D (TreanDa) Bicalutamide Antineoplastic Oral SoliD A2 A X (CasoDex) Bleomycin Antineoplastic Injection C C IARC Group 2B D (Blenoxane) Bortezomib Antineoplastic Injection C C D (VelcaDe) Bosentan Reproductive Oral SoliD A1 A Black Box warning on adverse reproductive effects X (Tracleer) Risk Busulfan Antineoplastic Oral SoliD A2 A IARC Group 1 carcinogen D (Myleran) Cabazitaxel Antineoplastic Injection C C D (Jevtana) Black Box warning for aplastic anemia; congenital Carbamazepine Non- Oral SoliD A1 A malformations in offspring of mothers who took Drug; D (Tegretol) Antineoplastic Oral LiquiD B1 B rapiD transplacental passage Carboplatin Antineoplastic Injection C C D (Paraplatin) Carfilzomib Special warnings on contraception while taking anD 2 Antineoplastic Injection C C D (Kyprolis) weeks post-treatment Generic Drug Name NIOSH Group Formulation Pharmacy Nursing Exposure Risk Information (Brand Name) Handling Handling NIOSH Supplemental Information Pregnancy Category Category Category Carmustine Antineoplastic Injection C C IARC Group 2A carcinogen; NTP*** D (BICNU) Chlorambucil Antineoplastic Oral SoliD A2 A IARC Group 1 carcinogen; NTP**. D (Leukeran) Chloramphenicol Non- Injection B1 B IARC Group 2A carcinogen; NTP*** D (Chloromycetin) Antineoplastic Cidofovir Non- Injection C C C (VistiDe) Antineoplastic Cisplatin Antineoplastic Injection C C IARC Group 2A carcinogen; NTP*** D (Platinol) Cladribine Antineoplastic Injection C C D (Leustatin) Clonazepam Reproductive IncreaseD risk of congenital abnormalities when taken Oral SoliD A1 A D (Klonopin) Risk in first trimester Published animal reproDuction anD Development Colchicine Reproductive stuDies inDicate it causes fetal toxicity, teratogenicity, Oral SoliD A1 A C (Colcrys) Risk anD altered postnatal Development at exposures within or above the clinical therapeutic range Cyclophosphamide Oral SoliD A2 A Antineoplastic IARC Group 1 carcinogen; NTP** D (Cytoxan) Injection C C Oral SoliD A1 A Cyclosporin Ophthalmic Non- B1 B (Neoral, SanDimmune, Drops IARC Group 1 carcinogen; NTP** C Antineoplastic Restasis) Oral LiquiD B1 B Injection B2 B Cytarabine (Cytosar-U, Depocyt) Antineoplastic Injection C C D Liposomal Cytarabine (Depocyt) Dacarbazine Antineoplastic Injection C C NTP*** C (DTIC) Dactinomycin (Cosmegen) Antineoplastic Injection C C D Daunorubicin (CerubiDine, Antineoplastic Injection C C IARC Group 2B, AKA daunomycin D Daumomycin, Daunosome) Generic Drug Name NIOSH Group Formulation Pharmacy Nursing Exposure Risk Information (Brand Name) Handling Handling NIOSH Supplemental Information Pregnancy Category Category Category Decitabine Antineoplastic Injection C C D (Dacogen) Degarelix Antineoplastic Injection C C X (Firmagon) SeconDary malignancies observed in patients treated long term with Razoxane (a racemic mixture Dexrazoxane Non- Injection B1 B containing Dexrazoxane); genotoxic in vitro anD in C (Totect, Zinecard) Antineoplastic vivo; in laboratory stuDies, testicular atrophy observeD at or below the human Dose Dinoprostone Reproductive Vaginal Insert B1 B HazarDous only for women in late pregnancy C (CerviDil, Prostin E2) Risk Oral SoliD A1 A Black Box warning for teratogenicity; tumors seen in Divalproex Non- Oral SoliD / laboratory stuDies at doses below the maximum D (Depakote) Antineoplastic A1 A Sprinkles recommenDeD human Dose Docetaxel Antineoplastic Injection C C D (Taxotere) Doxorubicin (ADriamycin, Doxil, LipoDox) Antineoplastic Injection C C IARC Group 2A carcinogen; NTP*** D Liposomal Doxorubicin (Doxil, LipoDox) DroneDarone Reproductive Oral SoliD A1 A Teratogenic in laboratory stuDies at ½ MRHD X (Multaq) Risk DutasteriDe Reproductive Oral SoliD A1 A Women warneD not to hanDle X (AvoDart) Risk
Load more

Recommended publications
  • PPE Requirements Hazardous Drug Handling
    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
    [Show full text]
  • Management of Status Epilepticus
    Published online: 2019-11-21 THIEME Review Article 267 Management of Status Epilepticus Ritesh Lamsal1 Navindra R. Bista1 1Department of Anaesthesiology, Tribhuvan University Teaching Address for correspondence Ritesh Lamsal, MD, DM, Department Hospital, Institute of Medicine, Tribhuvan University, Nepal of Anaesthesiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Tribhuvan University,Kathmandu, Nepal (e-mail: [email protected]). J Neuroanaesthesiol Crit Care 2019;6:267–274 Abstract Status epilepticus (SE) is a life-threatening neurologic condition that requires imme- diate assessment and intervention. Over the past few decades, the duration of seizure Keywords required to define status epilepticus has shortened, reflecting the need to start thera- ► convulsive status py without the slightest delay. The focus of this review is on the management of con- epilepticus vulsive and nonconvulsive status epilepticus in critically ill patients. Initial treatment ► neurocritical care of both forms of status epilepticus includes immediate assessment and stabilization, ► nonconvulsive status and administration of rapidly acting benzodiazepine therapy followed by nonbenzodi- epilepticus azepine antiepileptic drug. Refractory and super-refractory status epilepticus (RSE and ► refractory status SRSE) pose a lot of therapeutic problems, necessitating the administration of contin- epilepticus uous infusion of high doses of anesthetic agents, and carry a high risk of debilitating ► status epilepticus morbidity as well as mortality. ► super-refractory sta- tus epilepticus Introduction occur after 30 minutes of seizure activity. However, this working definition did not indicate the need to immediately Status epilepticus (SE) is a medical and neurologic emergency commence treatment and that permanent neuronal injury that requires immediate evaluation and treatment. It is associat- could occur by the time a clinical diagnosis of SE was made.
    [Show full text]
  • Ocps) Used in the NM Family Planning Program (FPP
    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
    [Show full text]
  • Aromasin (Exemestane)
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ADVERSE REACTIONS------------------------------­ These highlights do not include all the information needed to use • Early breast cancer: Adverse reactions occurring in ≥10% of patients in AROMASIN safely and effectively. See full prescribing information for any treatment group (AROMASIN vs. tamoxifen) were hot flushes AROMASIN. (21.2% vs. 19.9%), fatigue (16.1% vs. 14.7%), arthralgia (14.6% vs. 8.6%), headache (13.1% vs. 10.8%), insomnia (12.4% vs. 8.9%), and AROMASIN® (exemestane) tablets, for oral use increased sweating (11.8% vs. 10.4%). Discontinuation rates due to AEs Initial U.S. Approval: 1999 were similar between AROMASIN and tamoxifen (6.3% vs. 5.1%). Incidences of cardiac ischemic events (myocardial infarction, angina, ----------------------------INDICATIONS AND USAGE--------------------------- and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%. AROMASIN is an aromatase inhibitor indicated for: Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6, • adjuvant treatment of postmenopausal women with estrogen-receptor 6.1). positive early breast cancer who have received two to three years of • Advanced breast cancer: Most common adverse reactions were mild to tamoxifen and are switched to AROMASIN for completion of a total of moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%), five consecutive years of adjuvant hormonal therapy (14.1). fatigue (8% vs. 10%), increased sweating (4% vs. 8%), and increased • treatment of advanced breast cancer in postmenopausal women whose appetite (3% vs. 6%) for AROMASIN and megestrol acetate, disease has progressed following tamoxifen therapy (14.2). respectively (6, 6.1). ----------------------DOSAGE AND ADMINISTRATION----------------------- To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at Recommended Dose: One 25 mg tablet once daily after a meal (2.1).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • CEREBYX® (Fosphenytoin Sodium Injection)
    NDA 020450 Cerebyx (fosphenytoin sodium) Injection FDA Approved Labeling Text dated 10/2011 Page 1 of 22 CEREBYX® (Fosphenytoin Sodium Injection) WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES The rate of intravenous CEREBYX administration should not exceed 150 mg phenytoin sodium equivalents (PE) per minute because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering intravenous CEREBYX. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed (see WARNINGS and DOSAGE AND ADMINISTRATION). DESCRIPTION CEREBYX® (fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. 1.5 mg of fosphenytoin sodium is equivalent to 1 mg phenytoin sodium, and is referred to as 1 mg phenytoin sodium equivalents (PE). The amount and concentration of fosphenytoin is always expressed in terms of mg PE. CEREBYX is marketed in 2 mL vials containing a total of 100 mg PE and 10 mL vials containing a total of 500 mg PE. The concentration of each vial is 50 mg PE/mL. CEREBYX is supplied in vials as a ready-mixed solution in Water for Injection, USP, and Tromethamine, USP (TRIS), buffer adjusted to pH 8.6 to 9.0 with either Hydrochloric Acid, NF, or Sodium Hydroxide, NF. CEREBYX is a clear, colorless to pale yellow, sterile solution. The chemical name of fosphenytoin is 5,5-diphenyl-3-[(phosphonooxy)methyl]-2,4­ imidazolidinedione disodium salt.
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Calcium Channel Blocker As a Drug Candidate for the Treatment of Generalised Epilepsies
    UNIVERSITAT DE BARCELONA Faculty of Pharmacy and Food Sciences Calcium channel blocker as a drug candidate for the treatment of generalised epilepsies Final degree project Author: Janire Sanz Sevilla Bachelor's degree in Pharmacy Primary field: Organic Chemistry, Pharmacology and Therapeutics Secondary field: Physiology, Pathophysiology and Molecular Biology March 2019 This work is licensed under a Creative Commons license ABBREVIATIONS AED antiepileptic drug AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ANNA-1 antineuronal nuclear antibody 1 BBB blood-brain barrier Bn benzyl BnBr benzyl bromide BnNCO benzyl isocyanate Boc tert-butoxycarbonyl Bu4NBr tetrabutylammonium bromide Ca+2 calcium ion CACNA1 calcium channel voltage-dependent gene cAMP cyclic adenosine monophosphate CCB calcium channel blocker cGMP cyclic guanosine monophosphate CH3CN acetonitrile Cl- chlorine ion Cmax maximum concentration CMV cytomegalovirus CTScan computed axial tomography DCM dichloromethane DIPEA N,N-diisopropylethylamine DMF dimethylformamide DMPK drug metabolism and pharmacokinetics DNET dysembryoplastic neuroepithelial tumours EEG electroencephalogram EPSP excitatory post-synaptic potential FDA food and drug administration Fe iron FLIPR fluorescence imaging plate reader fMRI functional magnetic resonance imaging GABA γ-amino-α-hydroxybutyric acid GAD65 glutamic acid decarboxylase 65 GAERS generalised absence epilepsy rat of Strasbourg GluR5 kainate receptor GTC generalised tonic-clonic H+ hydrogen ion H2 hydrogen H2O dihydrogen dioxide (water)
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]